ForeFront

ForeFront, headquartered in Zhangjiang, Shanghai, focuses on the end-to-end development and commercialization of first generics, high-end generics, improved new drugs, and Class 1.1 innovative drugs. The company has comprehensively laid out multiple products targeting the global pulmonary arterial hypertension (PAH) drug market, which exceeds 7 billion US dollars. Its core product, Treprostinil Injection, has been launched in multiple specifications, while Treprostinil Inhalation Solution, Sapropterin Oral Tablets, and Iloprost Inhalation Solution are also under development. Dr. Ren Yi, the founder, is the former academic leader of Roche's US headquarters and a core member of Roche’s five global leadership committees, with 28 years of experience in R&D, production, and management.